Impact of Extensively Hydrolyzed Infant Formula on Circulating Lipids During Early Life

Santosh Lamichhane, Heli Siljander, Marja Salonen, Terhi Ruohtula, Suvi M Virtanen, Jorma Ilonen, Tuulia Hyötyläinen, Mikael Knip, Matej Orešič, Santosh Lamichhane, Heli Siljander, Marja Salonen, Terhi Ruohtula, Suvi M Virtanen, Jorma Ilonen, Tuulia Hyötyläinen, Mikael Knip, Matej Orešič

Abstract

Background: Current evidence suggests that the composition of infant formula (IF) affects the gut microbiome, intestinal function, and immune responses during infancy. However, the impact of IF on circulating lipid profiles in infants is still poorly understood. The objectives of this study were to (1) investigate how extensively hydrolyzed IF impacts serum lipidome compared to conventional formula and (2) to associate changes in circulatory lipids with gastrointestinal biomarkers including intestinal permeability.

Methods: In a randomized, double-blind controlled nutritional intervention study (n = 73), we applied mass spectrometry-based lipidomics to analyze serum lipids in infants who were fed extensively hydrolyzed formula (HF) or conventional, regular formula (RF). Serum samples were collected at 3, 9, and 12 months of age. Child's growth (weight and length) and intestinal functional markers, including lactulose mannitol (LM) ratio, fecal calprotectin, and fecal beta-defensin, were also measured at given time points. At 3 months of age, stool samples were analyzed by shotgun metagenomics.

Results: Concentrations of sphingomyelins were higher in the HF group as compared to the RF group. Triacylglycerols (TGs) containing saturated and monounsaturated fatty acyl chains were found in higher levels in the HF group at 3 months, but downregulated at 9 and 12 months of age. LM ratio was lower in the HF group at 9 months of age. In the RF group, the LM ratio was positively associated with ether-linked lipids. Such an association was, however, not observed in the HF group.

Conclusion: Our study suggests that HF intervention changes the circulating lipidome, including those lipids previously found to be associated with progression to islet autoimmunity or overt T1D.

Clinical trial registration: [Clinicaltrials.gov], identifier [NCT01735123].

Keywords: early life; extensively hydrolyzed infant formula; intestinal permeability; lipidome; lipidomics; metabolomics.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2022 Lamichhane, Siljander, Salonen, Ruohtula, Virtanen, Ilonen, Hyötyläinen, Knip and Orešič.

Figures

FIGURE 1
FIGURE 1
An overview of the study setting. Serum samples for lipidomic analysis were obtained from the Early Dietary Intervention and Later Signs of Beta-Cell Autoimmunity: Potential Mechanisms (EDIA) study which is a small-scale intervention trial comparing weaning infants onto an extensively hydrolyzed milk formula vs. a conventional cow’s milk-based formula. The study groups were matched by human leucocyte (HLA)-associated diabetes risk and period of birth. For each child, longitudinal samples were obtained corresponding to the ages of 3, 9, and 12 months. These age groups were selected with the objective of understanding the longitudinal lipid profiles in infants change after ingesting extensively hydrolyzed infant formula or conventional regular infant formula. Only, those children with information about amount of study formula per day were included in the data analysis.
FIGURE 2
FIGURE 2
Comparison of lipidome between the infants who consumed an extensively hydrolyzed milk formula vs. a conventional cow’s milk-based formula. (A) Total lipid concentration differences in each lipid class between the intervention groups. (B) Box plot showing selected lipid species representative of lipid classes that change at 3, 9, and 12 months of age when comparing the study groups. Here, HF stands for extensively hydrolyzed infant formula and RF for conventional regular infant formula.
FIGURE 3
FIGURE 3
Associations between serum lipids and gastrointestinal markers in the infants. (A) Comparison of lactulose mannitol ratio between HF vs. RF infants at 9 months of age. (B) Pairwise Spearman correlations as calculated between serum lipids and offspring gut inflammation marker and permeability. Here, FBD stands for fecal beta-defensin and FCP for fecal calprotectin. Correlations were calculated between simultaneous measurements at 9 months of age. Positive correlations marked in red, inverse correlations marked in blue. Dot size for each pairwise correlation corresponds to the strength of the calculated correlation.

References

    1. Kramer MS, Kakuma R. Optimal duration of exclusive breastfeeding. Cochrane Database Syst Rev. (2012) 2012:Cd003517.
    1. Agostoni C, Braegger C, Decsi T, Kolacek S, Koletzko B, Michaelsen KF, et al. Breast-feeding: a commentary by the ESPGHAN committee on nutrition. J Pediatr Gastroenterol Nutr. (2009) 49:112–25. 10.1097/MPG.0b013e31819f1e05
    1. Fleischer DM, Spergel JM, Assa’ad AH, Pongracic JA. Primary prevention of allergic disease through nutritional interventions. J Allergy Clin Immunol Pract. (2013) 1:29–36. 10.1016/j.jaip.2012.09.003
    1. Lemaire M, Le Huërou-Luron I, Blat S. Effects of infant formula composition on long-term metabolic health. J Dev Orig Health Dis. (2018) 9:573–89. 10.1017/S2040174417000964
    1. Grip T, Dyrlund TS, Ahonen L, Domellöf M, Hernell O, Hyötyläinen T, et al. Serum, plasma and erythrocyte membrane lipidomes in infants fed formula supplemented with bovine milk fat globule membranes. Pediatr Res. (2018) 84:726–32. 10.1038/s41390-018-0130-9
    1. Mennella JA, Trabulsi JC, Papas MA. Effects of cow milk versus extensive protein hydrolysate formulas on infant cognitive development. Amino Acids. (2016) 48:697–705. 10.1007/s00726-015-2118-7
    1. Sackesen C, Altintas DU, Bingol A, Bingol G, Buyuktiryaki B, Demir E, et al. Current trends in tolerance induction in cow’s milk allergy: from passive to proactive strategies. Front Pediatr. (2019) 7:372. 10.3389/fped.2019.00372
    1. Gerstein HC. Cow’s milk exposure and type I diabetes mellitus. a critical overview of the clinical literature. Diabetes Care. (1994) 17:13–9. 10.2337/diacare.17.1.13
    1. Virtanen SM, Kenward MG, Erkkola M, Kautiainen S, Kronberg-Kippilä C, Hakulinen T, et al. Age at introduction of new foods and advanced beta cell autoimmunity in young children with HLA-conferred susceptibility to type 1 diabetes. Diabetologia. (2006) 49:1512–21. 10.1007/s00125-006-0236-1
    1. Vojdani A. A potential link between environmental triggers and autoimmunity. Autoimmune Dis. (2014) 2014:437231. 10.1155/2014/437231
    1. Knip M, Virtanen SM, Seppä K, Ilonen J, Savilahti E, Vaarala O, et al. Dietary intervention in infancy and later signs of beta-cell autoimmunity. N Engl J Med. (2010) 363:1900–8. 10.1056/NEJMoa1004809
    1. Vaarala O, Ilonen J, Ruohtula T, Pesola J, Virtanen SM, Härkönen T, et al. Removal of bovine insulin from cow’s milk formula and early initiation of beta-cell autoimmunity in the FINDIA pilot study. Arch Pediatr Adolesc Med. (2012) 166:608–14. 10.1001/archpediatrics.2011.1559
    1. Visser JT, Bos NA, Harthoorn LF, Stellaard F, Beijer-Liefers S, Rozing J, et al. Potential mechanisms explaining why hydrolyzed casein-based diets outclass single amino acid-based diets in the prevention of autoimmune diabetes in diabetes-prone BB rats. Diabetes Metab Res Rev. (2012) 28:505–13. 10.1002/dmrr.2311
    1. Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke JD, Serino M, et al. Intestinal permeability–a new target for disease prevention and therapy. BMC Gastroenterol. (2014) 14:189. 10.1186/s12876-014-0189-7
    1. Hummel S, Beyerlein A, Tamura R, Uusitalo U, Andrén Aronsson C, Yang J, et al. First infant formula type and risk of islet autoimmunity in the environmental determinants of diabetes in the young (TEDDY) study. Diabetes Care. (2017) 40:398–404. 10.2337/dc16-1624
    1. Knip M, Åkerblom HK, Al Taji E, Becker D, Bruining J, Castano L, et al. Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 dabetes: the TRIGR randomized clinical trial. JAMA. (2018) 319:38–48. 10.1001/jama.2017.19826
    1. Laurens MLL, Kraus-Friedberg C, Kar W, Sanfilippo D, Rajasekaran S, Comstock SS. Dietary intake influences metabolites in healthy infants: a scoping review. Nutrients. (2020) 12:2073. 10.3390/nu12072073
    1. Phan M, Momin SR, Senn MK, Wood AC. Metabolomic insights into the effects of breast milk versus formula milk feeding in infants. Curr Nutr Rep. (2019) 8:295–306. 10.1007/s13668-019-00284-2
    1. Prell C, Koletzko B. Breastfeeding and complementary feeding. Dtsch Arztebl Int. (2016) 113:435–44.
    1. Li Q, Parikh H, Butterworth MD, Lernmark Å, Hagopian W, Rewers M, et al. Longitudinal metabolome-wide signals prior to the appearance of a first islet autoantibody in children participating in the TEDDY study. Diabetes. (2020) 69:465–76. 10.2337/db19-0756
    1. Oresic M, Simell S, Sysi-Aho M, Näntö-Salonen K, Seppänen-Laakso T, Parikka V, et al. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med. (2008) 205:2975–84. 10.1084/jem.20081800
    1. Lamichhane S, Ahonen L, Dyrlund TS, Kemppainen E, Siljander H, Hyöty H, et al. Dynamics of plasma lipidome in progression to islet autoimmunity and type 1 diabetes - type 1 diabetes prediction and prevention study (DIPP). Sci Rep. (2018) 8:10635. 10.1038/s41598-018-28907-8
    1. Hermann R, Turpeinen H, Laine AP, Veijola R, Knip M, Simell O, et al. HLA DR-DQ-encoded genetic determinants of childhood-onset type 1 diabetes in finland: an analysis of 622 nuclear families. Tissue Antigens. (2003) 62:162–9. 10.1034/j.1399-0039.2003.00071.x
    1. Sen P, Carlsson C, Virtanen SM, Simell S, Hyöty H, Ilonen J, et al. Persistent alterations in plasma lipid profiles before introduction of gluten in the diet associated with progression to celiac disease. Clin Transl Gastroenterol. (2019) 10:1–10. 10.14309/ctg.0000000000000044
    1. Siljander H, Jason E, Ruohtula T, Selvenius J, Koivusaari K, Salonen M, et al. Effect of early feeding on intestinal permeability and inflammation markers in infants with genetic susceptibility to type 1 diabetes: a randomized clinical trial. J Pediatr. (2021) 238:305–11.e3. 10.1016/j.jpeds.2021.07.042
    1. Nygren H, Seppänen-Laakso T, Castillo S, Hyötyläinen T, Orešič M. Liquid chromatography-mass spectrometry (LC-MS)-based lipidomics for studies of body fluids and tissues. Methods Mol Biol. (2011) 708:247–57. 10.1007/978-1-61737-985-7_15
    1. Pluskal T, Castillo S, Villar-Brione A, Orešič M. MZmine 2: modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinformatics. (2010) 11:395. 10.1186/1471-2105-11-395
    1. Yassour M, Jason E, Hogstrom LJ, Arthur TD, Tripathi S, Siljander H, et al. Strain-level analysis of mother-to-child bacterial transmission during the first few months of life. Cell Host Microbe. (2018) 24:146–54.e4. 10.1016/j.chom.2018.06.007
    1. Segata N, Waldron L, Ballarini A, Narasimhan V, Jousson O, Huttenhower C. Metagenomic microbial community profiling using unique clade-specific marker genes. Nat Methods. (2012) 9:811–4. 10.1038/nmeth.2066
    1. Northrop CA, Lunn PG, Behrens RH. Automated enzymatic assays for the determination of intestinal permeability probes in urine. 1. lactulose and lactose. Clin Chim Acta. (1990) 187:79–87. 10.1016/0009-8981(90)90333-n
    1. Blood J, Ingle AR, Allison N, Davies GR, Hill PG. Rapid enzymatic method for the measurement of mannitol in urine. Ann Clin Biochem. (1991) 28 (Pt 4):401–6. 10.1177/000456329102800416
    1. Tøn H, Brandsnes, Dale S, Holtlund J, Skuibina E, Schjønsby H, et al. Improved assay for fecal calprotectin. Clin Chim Acta. (2000) 292:41–54. 10.1016/s0009-8981(99)00206-5
    1. Wehkamp J, Fellermann K, Herrlinger KR, Baxmann S, Schmidt K, Schwind B, et al. Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur J Gastroenterol Hepatol. (2002) 14:745–52. 10.1097/00042737-200207000-00006
    1. Acharjee A, Prentice P, Acerini C, Smith J, Hughes IA, Ong K, et al. The translation of lipid profiles to nutritional biomarkers in the study of infant metabolism. Metabolomics. (2017) 13:25. 10.1007/s11306-017-1166-2
    1. Gault CR, Obeid LM, Hannun YA. An overview of sphingolipid metabolism: from synthesis to breakdown. Adv Exp Med Biol. (2010) 688:1–23. 10.1007/978-1-4419-6741-1_1
    1. Schneider N, Hauser J, Oliveira M, Cazaubon E, Mottaz SC, O’Neill BV, et al. Sphingomyelin in brain and cognitive development: preliminary data. eNeuro. (2019) 6:ENEURO.421–418. 10.1523/ENEURO.0421-18.2019
    1. Tanaka K, Hosozawa M, Kudo N, Yoshikawa N, Hisata K, Shoji H, et al. The pilot study: sphingomyelin-fortified milk has a positive association with the neurobehavioural development of very low birth weight infants during infancy, randomized control trial. Brain Dev. (2013) 35:45–52. 10.1016/j.braindev.2012.03.004
    1. Al-Sari N, Schmidt S, Suvitaival T, Kim M, Trošt K, Ranjan AG, et al. Changes in the lipidome in type 1 diabetes following low carbohydrate diet: post-hoc analysis of a randomized crossover trial. Endocrinol Diab Metab. (2021) 4:e00213. 10.1002/edm2.213
    1. Drobnik W, Liebisch G, Audebert FX, Frohlich D, Gluck T, Vogel P, et al. Plasma ceramide and lysophosphatidylcholine inversely correlate with mortality in sepsis patients. J Lipid Res. (2003) 44:754–61. 10.1194/jlr.M200401-JLR200
    1. Perrin-Cocon L, Agaugué S, Coutant F, Saint-Mézard P, Guironnet-Paquet A, Nicolas JF, et al. Lysophosphatidylcholine is a natural adjuvant that initiates cellular immune responses. Vaccine. (2006) 24:1254–63. 10.1016/j.vaccine.2005.09.036
    1. Radu CG, Yang LV, Riedinger M, Au M, Witte ON. T cell chemotaxis to lysophosphatidylcholine through the G2A receptor. Proc Natl Acad Sci USA. (2004) 101:245–50. 10.1073/pnas.2536801100
    1. Ahmadian M, Duncan RE, Jaworski K, Sarkadi-Nagy E, Sul HS. Triacylglycerol metabolism in adipose tissue. Future Lipidol. (2007) 2:229–37. 10.2217/17460875.2.2.229
    1. Stonehouse W, Benassi-Evans B, James-Martin G, Abeywardena M. Fatty acid regio-specificity of triacylglycerol molecules may affect plasma lipid responses to dietary fats-a randomised controlled cross-over trial. Eur J Clin Nutr. (2020) 74:268–77. 10.1038/s41430-019-0452-7
    1. Schwab U, Reynolds AN, Sallinen T, Rivellese AA, Risérus U. Dietary fat intakes and cardiovascular disease risk in adults with type 2 diabetes: a systematic review and meta-analysis. Eur J Nutr. (2021) 60:3355–63. 10.1007/s00394-021-02507-1
    1. Mendonça MA, Araújo WMC, Borgo LA, Alencar ER. Lipid profile of different infant formulas for infants. PLoS One. (2017) 12:e0177812. 10.1371/journal.pone.0177812
    1. Zhou AL, Ward RE. Milk polar lipids modulate lipid metabolism, gut permeability, and systemic inflammation in high-fat-fed C57BL/6J ob/ob mice, a model of severe obesity. J Dairy Sci. (2019) 102:4816–31. 10.3168/jds.2018-15949
    1. Yeruva L, Spencer NE, Saraf MK, Hennings L, Bowlin AK, Cleves MA, et al. Erratum to: formula diet alters small intestine morphology, microbial abundance and reduces VE-cadherin and IL-10 expression in neonatal porcine model. BMC Gastroenterol. (2016) 16:55. 10.1186/s12876-016-0469-5
    1. Ho NT, Li F, Lee-Sarwar KA, Tun HM, Brown BP, Pannaraj PS, et al. Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations. Nat Commun. (2018) 9:4169. 10.1038/s41467-018-06473-x
    1. Ghosh SS, Wang J, Yannie PJ, Ghosh S. Intestinal barrier dysfunction, LPS translocation, and disease development. J Endocr Soc. (2020) 4:bvz039. 10.1210/jendso/bvz039
    1. Baptista LC, Sun Y, Carter CS, Buford TW. Crosstalk between the gut microbiome and bioactive lipids: therapeutic targets in cognitive frailty. Front Nutr. (2020) 7:17. 10.3389/fnut.2020.00017
    1. Kok CR, Brabec B, Chichlowski M, Harris CL, Moore N, Wampler JL, et al. Stool microbiome, pH and short/branched chain fatty acids in infants receiving extensively hydrolyzed formula, amino acid formula, or human milk through two months of age. BMC Microbiol. (2020) 20:337. 10.1186/s12866-020-01991-5
    1. Gilley S, Ruebel M, Sims C, Zhong Y, Chintapalli S, Turner D, et al. Alterations in the gut microbiome of infants consuming partially hydrolyzed cow milk protein formula. Curr Dev Nutr. (2021) 5(Suppl. 2):750–750. 10.1093/cdn/nzab046_047

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner